Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bortezomib in preparation of medicine for treating osteosarcoma

A technology for bortezomib and osteosarcoma, which is used in antitumor drugs, drug combinations, bone diseases, etc.

Active Publication Date: 2020-01-03
XI AN JIAOTONG UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, with the advancement of surgical techniques, the research of effective chemotherapy drugs, and the application of adjuvant chemotherapy and radiotherapy before and after surgery, the 5-year survival rate of osteosarcoma patients has been greatly improved. However, recurrent and metastatic osteosarcoma Cancer is still an incurable disease that needs to be overcome urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bortezomib in preparation of medicine for treating osteosarcoma
  • Application of bortezomib in preparation of medicine for treating osteosarcoma
  • Application of bortezomib in preparation of medicine for treating osteosarcoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The present invention will be described in detail below in conjunction with the accompanying drawings.

[0022] The invention discloses a new function of the proteasome inhibitor bortezomib for treating osteosarcoma. Bortezomib can not only induce osteosarcoma cell apoptosis, but also low concentration of bortezomib can induce osteogenic differentiation of osteosarcoma cells, specifically manifested as increased calcified nodules in osteosarcoma cells F5M2 and U-2OS; alkaline phosphate Enzyme (ALP) activity increased; expression of osteogenic differentiation markers (ALP, OPN, Runx2) increased. The present invention will be further described in detail below in conjunction with specific examples (the human osteosarcoma cell lines used in the experiment are F5M2 and U-2OS), which are explanations rather than limitations of the present invention.

[0023] The present invention uses Annexin V-FITC / 7-AAD double-staining flow cytometry to detect the killing effect of bortezo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of bortezomib in preparation of medicine for treating osteosarcoma. A new function of the proteasome inhibitor bortezomib is provided, that is, the bortezomib can be used for directionally inducing osteogenic differentiation of osteosarcoma and can be used for treating the osteosarcoma. Through experimental verification, while bortezomib of medium and high concentrations induces apoptosis of osteosarcoma cells, bortezomib of low concentration can further induce osteogenic differentiation of the osteosarcoma cells, specifically, calcific nodules in the osteosarcoma cells F5M2 and U-2 OS are increased by the bortezomib; alkaline phosphatase activity is increased; and expression of osteogenic differentiation markers (ALP, OPN, Runx2) is increased.

Description

technical field [0001] The invention relates to the application of bortezomib in the preparation of medicines for treating osteosarcoma Background technique [0002] The ubiquitin-proteasome pathway (UPP) is an important proteolytic pathway in living cells. The hydrolysis process mainly occurs in the 26S proteasome, which consists of two 19S regulatory complexes and a 20S catalytic core body. The 20S catalytic core is responsible for decomposing polyubiquitinated substrate proteins into polypeptide fragments. It is a tubular structure composed of stacked six-leafed rings containing different α and β subunits, and the active subunit is β1 , β2 and β5. Studies have confirmed that the proteasome participates in the degradation of various proteins (such as NF-κB, p53, cyclin, etc.), and indirectly regulates biological processes such as cell mitosis, apoptosis, signal transduction, and protein transmembrane localization. It is closely related to many diseases such as schizophr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/05A61P19/00A61P35/00
CPCA61K38/05A61P19/00A61P35/00
Inventor 胡劲松张丹雷莉陈萍贾茜
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com